Bluejay Diagnostics Files 8-K with Material Agreement
Ticker: BJDX · Form: 8-K · Filed: 2024-06-28T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
Bluejay Diagnostics signed a material agreement, filed an 8-K. Check for details.
AI Summary
On June 27, 2024, Bluejay Diagnostics, Inc. entered into a Material Definitive Agreement. The company also reported other events and filed financial statements and exhibits. The filing details are associated with Accession Number 0001213900-24-057240.
Why It Matters
This 8-K filing indicates a significant development for Bluejay Diagnostics, Inc., potentially impacting its operations and future financial performance.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities, and the nature of this agreement is not fully detailed in the provided text.
Key Players & Entities
- Bluejay Diagnostics, Inc. (company) — Registrant
- June 27, 2024 (date) — Date of earliest event reported
- 0001213900-24-057240 (other) — Accession Number
- 360 Massachusetts Avenue, Suite 203 (address) — Principal executive offices
- Acton, MA 01720 (address) — Principal executive offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Bluejay Diagnostics, Inc.?
The provided text states that Bluejay Diagnostics, Inc. entered into a Material Definitive Agreement on June 27, 2024, but does not specify the details of the agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 27, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.
What is the SEC file number for Bluejay Diagnostics, Inc.?
The SEC file number for Bluejay Diagnostics, Inc. is 001-41031.
What is the accession number for this 8-K filing?
The accession number for this 8-K filing is 0001213900-24-057240.
Filing Stats: 1,683 words · 7 min read · ~6 pages · Grade level 11.2 · Accepted 2024-06-28 16:49:32
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share BJDX The Nasdaq Stock Mar
- $0 — luding one share of common stock, minus $0.0001, and the remaining exercise price
- $1.96 — rants have an initial exercise price of $1.96 per share of common stock, and will exp
- $2.3 million — proceeds from the offering to (i) repay $2.3 million in outstanding debt that will be due an
- $75,000 — expense allowance to the Underwriter of $75,000 and (b) to reimburse the Underwriter fo
- $170,000 — s, including, but not limited to, up to $170,000 for reasonable legal fees and disbursem
Filing Documents
- ea0208666-8k_bluejay.htm (8-K) — 36KB
- ea020866601ex1-1_bluejay.htm (EX-1.1) — 253KB
- ea020866601ex4-1_bluejay.htm (EX-4.1) — 105KB
- ea020866601ex4-2_bluejay.htm (EX-4.2) — 137KB
- ea020866601ex4-3_bluejay.htm (EX-4.3) — 116KB
- ea020866601ex99-1_bluejay.htm (EX-99.1) — 12KB
- ea020866601ex99-2_bluejay.htm (EX-99.2) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-2_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-057240.txt ( ) — 1016KB
- bjdx-20240627.xsd (EX-101.SCH) — 3KB
- bjdx-20240627_lab.xml (EX-101.LAB) — 33KB
- bjdx-20240627_pre.xml (EX-101.PRE) — 22KB
- ea0208666-8k_bluejay_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On June 27, 2024, the Company issued a press release announcing the pricing of the Offering. On June 28, 2024, the Company issued a press release announcing the closing of the Offering. Copies of the press releases are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are hereby incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 1.1 Underwriting Agreement 4.1 Form of Prefunded Warrant 4.2 Form of Class C Warrant 4.3 Form of Class D Warrant 99.1 Press Release dated June 27, 2024 99.2 Press Release dated June 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BLUEJAY DIAGNOSTICS, INC. Date: June 28, 2024 By: /s/ Neil Dey Name: Neil Dey Title: Chief Executive Officer 3